iTeos Therapeutics

iTeos Therapeutics is a next-generation immuno-oncology company developing innovative anti-cancer agents to fulfil the promise of immunotherapy by targeting the tumor microenvironment to improve the lives of people living with cancer.

iTeos Therapeutics is dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design.

iTeos Therapeutics was founded in 2011 by Benoit Van den Eynde and Michel Detheux. The company is headquartered in Gosselies, Hainaut, Belgium and Cambridge, Massachusetts.

 

iTeos Therapeutics is targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs). The Company’s lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study. Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020.

 

iTeos Therapeutics is backed by MPM Capital, RA Capital Management, Boxer Capital, Janus Henderson Investors, HBM Partners, 6 Dimensions Capital, Curative Ventures and others. The company raised $125M in Series B2 financing on Apr 01, 2020. This brings iTeos' total funding to $215M to date.

 

 

  • Year founded: 2011
  • Funding Info: $215M over 4 Rounds (Latest Funding Type: Series B2)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Gosselies
  • State: Hainaut
  • Country: Belgium
Related businesses